RecruitingNCT06978387
The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes.
Sponsor
Attikon Hospital
Enrollment
90 participants
Start Date
Jan 15, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
In this cross-sectioanl study, 90 patients aged \>12 years old with T1DM who are on MiniMed 780G system will be included.The investigators aim to assesse the association of patients' adherence to Mediterranean diet (MD) with CGM and insulin metrics, as well as anthropometric measurements, BMI, lipid levels and blood pressure.Moreover, markers of endothelial, cardiovascular and liver function will be also assessed and associated with the use of Minimed 780G and the adherence to MD.
Eligibility
Min Age: 12 YearsMax Age: 80 Years
Inclusion Criteria5
- Clinical diagnosis of type 1 diabetes \>1 year prior to consent date. Diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.
- HbA1c \< 12.5%
- Age \>7years at the initiation of the system
- Patients with Minimed 780G
- History of 3 clinic visits in the last year
Exclusion Criteria1
- Diabetic Ketoacidosis in the 6 months prior to screening visits
Interventions
DEVICEMinimed 780G
patients aged \>12 years old with T1DM who are on MiniMed 780G
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06978387
Related Trials
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT063246044 locations
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
NCT060148791 location
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT061987251 location
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
NCT072121791 location
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
NCT0706157411 locations